Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
作者信息
Cadegiani Flávio A
机构信息
Adrenal and Hypertension Unit, Endocrinology, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.
出版信息
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E587-E588. doi: 10.1152/ajpendo.00136.2020.
Abstract
摘要
相似文献
1
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?螺内酯能否用于预防高血压患者的新型冠状病毒肺炎诱导的急性呼吸窘迫综合征？
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E587-E588. doi: 10.1152/ajpendo.00136.2020.
2
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).螺内酯可能提供针对 SARS-CoV-2 的保护：靶向雄激素、血管紧张素转换酶 2（ACE2）和肾素-血管紧张素-醛固酮系统（RAAS）。
Med Hypotheses. 2020 Oct;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub 2020 Jul 16.
3
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
4
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
5
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.在对COVID-19中的RAS阻断进行快速判断之前的可靠科学依据。
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716. doi: 10.2215/CJN.03530320. Epub 2020 Mar 27.
6
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
7
Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.对策与治疗：A(1 - 7)用于治疗由COVID - 19感染引起的急性呼吸窘迫综合征。
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320972018. doi: 10.1177/1470320320972018.
8
Considerations for Statin Therapy in Patients with COVID-19.新型冠状病毒肺炎患者他汀类药物治疗的考量因素
Pharmacotherapy. 2020 May;40(5):484-486. doi: 10.1002/phar.2397. Epub 2020 May 4.
9
Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock.新冠肺炎、ARDS 和感染性休克患者对血管紧张素 II 的血压敏感性意外增加。
Chest. 2020 Aug;158(2):e55-e58. doi: 10.1016/j.chest.2020.04.015. Epub 2020 Apr 23.
10
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
引用本文的文献
1
Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.缝隙连接蛋白 1 通道和嘌呤能受体在 SARS-CoV-2 发病机制和作用机制中的可能作用，以及针对它们在 COVID-19 中的治疗潜力。
Life Sci. 2022 May 15;297:120482. doi: 10.1016/j.lfs.2022.120482. Epub 2022 Mar 11.
2
COVID-19 in Ophthalmology. Current Disease Status and Challenges during Clinical Practice.眼科领域的新型冠状病毒肺炎。临床实践中的当前疾病状况与挑战。
Maedica (Bucur). 2021 Dec;16(4):668-680. doi: 10.26574/maedica.2020.16.4.668.
3
ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study.ACE 基因变异使高血压、血脂异常或糖尿病患者患严重 COVID-19 的风险增加：一项西班牙试点研究。
Front Endocrinol (Lausanne). 2021 Aug 19;12:688071. doi: 10.3389/fendo.2021.688071. eCollection 2021.
4
Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?SARS-CoV-2 感染的基本机制。哪些内分泌系统可能受到牵连？
Rev Endocr Metab Disord. 2022 Apr;23(2):137-150. doi: 10.1007/s11154-021-09678-6. Epub 2021 Jul 31.
5
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.在门诊环境中，早期使用阿奇霉素联合硝唑尼特、伊维菌素或羟氯喹治疗COVID-19，与未治疗患者的已知结局相比，显著改善了COVID-19的治疗结果。
New Microbes New Infect. 2021 Sep;43:100915. doi: 10.1016/j.nmni.2021.100915. Epub 2021 Jul 7.
6
Drug repurposing for COVID-19: Approaches, challenges and promising candidates.新冠病毒药物再利用：方法、挑战与有前景的候选药物。
Pharmacol Ther. 2021 Dec;228:107930. doi: 10.1016/j.pharmthera.2021.107930. Epub 2021 Jun 23.
7
Shedding light on therapeutics in alopecia and their relevance to COVID-19.揭示脱发治疗方法及其与COVID-19的相关性。
Clin Dermatol. 2021 Jan-Feb;39(1):76-83. doi: 10.1016/j.clindermatol.2020.12.015. Epub 2020 Dec 16.
8
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).非那雄胺早期抗雄激素治疗可减少男性 COVID-19 患者的病毒脱落、炎症反应和缓解时间：一项随机、双盲、安慰剂对照干预试验（EAT-DUTA AndroCoV 试验 - 生化研究）
Cureus. 2021 Feb 1;13(2):e13047. doi: 10.7759/cureus.13047.
9
To Curb the Progression of Fatal COVID-19 Course-Dream or Reality.遏制致命 COVID-19 病程进展——梦想还是现实。
Curr Hypertens Rep. 2021 Feb 27;23(2):12. doi: 10.1007/s11906-021-01130-z.
10
Profil clinique, biologique et radiologique des patients Algériens hospitalisés pour COVID-19: données préliminaires.阿尔及利亚 COVID-19 住院患者的临床、生物学和影像学特征：初步数据。
Pan Afr Med J. 2020 Jun 15;35(Suppl 2):77. doi: 10.11604/pamj.supp.2020.35.2.23807. eCollection 2020.
本文引用的文献
1
COVID-19, ACE2, and the cardiovascular consequences.新型冠状病毒肺炎、血管紧张素转化酶 2 与心血管系统并发症
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090. doi: 10.1152/ajpheart.00217.2020. Epub 2020 Mar 31.
2
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
5
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?可溶性血管紧张素转化酶 2：冠状病毒感染治疗的潜在方法？
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
6
The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.新型冠状病毒肺炎（COVID-19）的潜伏期来自公开报告的确诊病例：估计和应用。
Ann Intern Med. 2020 May 5;172(9):577-582. doi: 10.7326/M20-0504. Epub 2020 Mar 10.
7
Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease.分析与 2019 年新型冠状病毒病住院患者疾病结局相关的因素。
Chin Med J (Engl). 2020 May 5;133(9):1032-1038. doi: 10.1097/CM9.0000000000000775.
8
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
9
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
10
Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling.血管紧张素转换酶 2 活性与人类心房颤动：血浆血管紧张素转换酶 2 活性增加与心房颤动和更严重的左心房结构重构相关。
Europace. 2017 Aug 1;19(8):1280-1287. doi: 10.1093/europace/euw246.
Zotero 插件